Sweden
· Delayed Price · Currency is SEK Nanexa AB Company Description
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America.
The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances.
It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma.
The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances.
Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
| Country | Sweden |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 15 |
| CEO | David Westberg |
Contact Details
Address: Virdings Allé 2 Uppsala, 75450 Sweden | |
| Phone | 46 18 10 03 00 |
| Website | nanexa.com |
Stock Details
| Ticker Symbol | NANEXA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007074166 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Westberg | Chief Executive Officer |
| Marten Rooth | Co-Founder and Chief Technology Officer |
| Anders Johansson | Co-Founder and Head of Intellectual Property |
| Cecilia Danckwardt-Lilliestrom | Chief Financial Officer |
| Mikael Asp | Head of QA and Special Advisor |
| Joel Hellrup | Head of Pharmaceutical Research & Development |
| Polla Rouf | Head of ALD Research & Development |
| Bridget Lacey B.Sc. | Chief Business Officer |
| Otto Skolling M.Sc | Director of Business Development |